Patent strategies for biotechnology enterprises

BioPharm International

Volumn 20, Issue 8, 2007, Pages 56-64

  Li, Wei ^a   Yu, Xiang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTECHNOLOGY; COMPETITION; DRUG INDUSTRY; LAW SUIT; LICENSING; MEDICAL RESEARCH; PATENT; REVIEW; STRATEGIC PLANNING;

EID: 34548294144     PISSN: 1542166X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (15)

1. Organisation for Economic Cooperation and Development (OECD). OECD policy brief: Intellectual property and competition policy in the biotechnology industry. Paris: OECD Headquarters; 2005 June.
2. Isacson JP. Maximizing profits through intelligent planning and implementation. Nat Biotechnol 2000 May;18(5):565-6.
3. Amgen, Inc. vs Hoechst Marion Roussel, Inc., 3F supp 2d 104 (D Mass 1998). Amgen, Inc. vs Elanex Parm., Inc., No C93-1483D, 1996 WL 84590 (WD Wash Feb 6, 1996). Amgen, Inc. vs Genetics Inst., Inc., 877 F supp 45 (D Mass 1995) affd, 98 F3d 1328 (Fed Cir 1996).
4. Brown RJ, Levitt KE. An effective patent strategy: What it is, and how to implement it. Hennepin Lawyer 2003 Mar;72(3):16-23.
5. Lanjouw J, Schankerman M. Stylized facts of patent litigation: Value, scope and ownership. National Bureau of Economic Research Working Paper No. W6297. Cambridge (MA): National Bureau of Economic Research; 1997.
6. Lanjouw J, Schankerman M. Characteristics of patent litigation: A window on competition. Rand J of Econ 2001 Spr;32(1):129-51.
7. Lanjouw J, Schankerman M. An empirical analysis of the enforcement of patent rights in the United States. In: Cohen WM, Merrill S, editors. Patents in the knowledge-based economy. Washington: National Academy Press; 2003.
8. Organisation for Economic Cooperation and Development (OECD). Patents, innovation and economic performance. Proceedings of the OECD Conference on Intellectual Property Rights, Innovation and Economic Performance; 2003 Aug 28-29; Paris, France. Paris: OECD Headquarters; 2003.
9. Miele AL. Patent strategy: The manager's guide to profiting from patent portfolios. Hoboken (NJ): John Wiley & Sons; 2001.
10. McGarrigle P. Qtd in: Huebner SR. Orientation in the patent jungle. European Private Equity and Venture Capital Association (EVCA) Conference Journal [online] 2005 Oct 19-21[cited 2007 Jul 1]:10. Available from: URL: http://www.kennet.com/images/Conference_Journal_2005.pdf
11. Grindley PC, Teece DJ. Managing intellectual capital: Licensing and cross-licensing in semiconductors and electronics. California Mgt Rev 1997;29:8-41.
12. Shapiro C. Antitrust limits to patent settlements. Rand J of Econ 2003 Su;34(2): 391-411.
13. Hyseq vs Affymetrix, No 97-20188 (ND Cal Mar 3, 1997). See Rouse R, Hardiman G. Microarray technology - An intellectual property perspective, 4 Pharmacogenomics 2003;4(5);623-32.
14. Levy IJ, Fernands AM. Building a strong case for the defence. Intellectual Asset Mgt 2006 Feb; Special Report, IP Value in the Life Sciences Industries:17-20.
15. Yeh JJ, Fernandez D, Hansen N. Patent prosecution strategies for stem cell-related applications. J of the Patent and Trademark Office Soc [online] 2006 Jan [cited 2007 July 1];88(1). Available from: http://www.jptos.org/pages. php?menuid=22&pagenum=2